Saturday 17 October 2026 Export NCNA’s income statement to Excel — free account

NuCana PLC Sponsored ADR

In the quarter to June 2026, EPS fell 16,379.7% and free cash flow grew 55.7%, each against the same quarter a year earlier.

0.99 0.03 −2.94%

Follow NCNA

Alert me

Market cap: $4.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4.40

Revenue —

Net Income (12.52)

Free Cash Flow (7.02)

Net Debt (26.17)

Current Ratio 4.73

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 85.04%

Next Y EPS Growth 0.00%

Next Y revenue growth —

Next 5Y EPS Growth 0.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 4.00%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21	9	32	26
Receivables	6	6	2	3
Inventory	—	—	—	—
Other	—	—	—	—
	31	16	35	31

	2023	2024	2025	Q'26
Payables	4	3	1	1
ST’ Debt	—	—	—	—
Other	—	0	—	—
	16	11	6	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(24.11%)	(12.34%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(4)	(6)	2	(1)	(10)
’24	(7)	(1)	(6)	(9)	(24)
’23	(13)	(8)	(13)	0	(33)
’22	(12)	(11)	3	(9)	(29)
’21	(11)	(7)	(1)	(14)	(33)
’20	(8)	(2)	(7)	(11)	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(4)	(6)	2	(1)	(10)
’24	(8)	(2)	(6)	(9)	(25)
’23	(13)	(8)	(10)	0	(30)
’22	(12)	(11)	3	(10)	(29)
’21	(11)	(7)	(5)	(14)	(38)
’20	(8)	(2)	(8)	(12)	(30)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.25k)	(986.56)	—	—	—
’25	(126.00)	(5.99)	(0.51)	(1.47)	(17.23)
’24	(32.00)	(31.16)	(19.42)	(64.00)	(1.66k)
’23	(900.00)	(650.00)	(800.00)	(850.00)	(3.30k)
’22	(1.05k)	(450.00)	(550.00)	(1.70k)	(3.75k)
’21	(1.30k)	(1.20k)	(1.05k)	(1.75k)	(5.35k)
’20	(750.00)	(1.20k)	(1.55k)	(1.60k)	(5.20k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	46,600.00	47,400.00	20,050.00	19,050.00	9,400.00	2,585.00	1,130.00	212.00	2.78	Analyst estimates 2026–2028 Powerpack
	High	—	99,750.00	160,000.00	96,400.00	52,950.00	39,150.00	16,600.00	8,750.00	3,880.00	274.00
People
People	Employees	16	20	24	31	29	33	31	28	22	12
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(11)	(33)	(24)	(33)	(46)	(66)	(48)	(40)	(29)	(40)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(8)	(30)	(18)	(27)	(39)	(56)	(40)	(34)	(24)	(39)
	Depreciation	0	0	0	1	1	1	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1,694.12)	(5,750.00)	(2,850.00)	(4,200.00)	(5,200.00)	(5,350.00)	(3,750.00)	(3,300.00)	(1,662.00)	(17.23)
	Cash flow	(2,615.73)	(2,158.25)	(2,549.47)	(4,681.91)	(3,652.47)	(3,150.04)	(2,754.24)	(3,132.14)	(2,181.33)	(4.38)
	Capex	(156.42)	(271.40)	(338.70)	(247.71)	(275.72)	(484.19)	(61.61)	250.91	(33.43)	(0.11)
	Free cash flow	(2,772.15)	(2,429.65)	(2,888.17)	(4,929.62)	(3,928.20)	(3,634.23)	(2,815.85)	(2,881.23)	(2,214.76)	(4.50)
	Book value	7,126.90	23,153.79	17,017.45	12,478.65	16,764.64	8,666.84	4,579.14	1,763.61	679.34	14.28
	Shares, m	0	0	0	0	0	0	0	0	0	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(13)	(11)	(16)	(30)	(28)	(33)	(29)	(33)	(24)	(10)
	Capex	(1)	(1)	(2)	(2)	(2)	(5)	(1)	3	0	0
	Free cash flow	(13)	(13)	(18)	(32)	(30)	(38)	(29)	(30)	(25)	(10)
Balance, $m
Balance, $m	Working capital	32	117	104	75	120	82	44	15	5	29
	Total debt	—	—	—	1	1	1	1	—	—	—
	Net debt	(27)	(112)	(103)	(66)	(112)	(83)	(52)	(21)	(9)	(32)
	Shareholders’ equity	34	120	109	81	127	90	48	19	8	32
Returns, %
Returns, %	ROA	(10.00)	(36.94)	(15.36)	(26.53)	(34.54)	(45.51)	(44.36)	(64.46)	(90.80)	(132.97)
	ROIC	(107.68)	(223.69)	(297.89)	(138.85)	(173.43)	(569.78)	0.00	0.00	0.00	(16,444.30)
	ROE	(10.41)	(38.49)	(16.11)	(28.78)	(37.79)	(51.24)	(57.50)	(103.93)	(185.84)	(195.06)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PCSA Heatwurx Inc.	$4.7M	1.6×	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
DRMA Dermata Therapeutics, Inc.	$4.5M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$4.5M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
NCNA NuCana PLC Sponsored ADR	$4.4M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.3M	1.0×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
LIMN Liminatus Pharma Inc.	$4.3M	— (loss-making)	—	—	n/m	+89.00% (above 0%: growing)	—	0.00%	Compare
LNAI Lunai Bioworks Inc.	$4.2M	— (loss-making)	—	—	n/m	−1.65% (below 0%: shrinking)	100.00%	(6,877.49%)	Compare
JUNS Jupiter Neurosciences, Inc.	$4.1M	— (loss-making)	—	—	n/m	−177.06% (below 0%: shrinking)	87.19%	(11,334.30%)	Compare
Median of peers	$4.4M	1.0×	—	−64.29%	—	+15.14%	23.77%	0.00%

All 614 Biotechnology stocks →

NuCana PLC Sponsored ADR (NCNA) key facts

NuCana PLC Sponsored ADR (NCNA) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, NCNA traded at $0.99, a market capitalization of $4.4 million.
Return on equity was −195.1% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.